Gefitinib disrupts K-ras/PI3K and K-ras/Raf complexes in human nonsmall cell lung cancer (NSCLC) Calu3 cells, but not in Calu3 K-ras mutant cells [12, 14]. The gene discussed is KRAS; the disease is lung cancer.